{
    "nct_id": "NCT03981822",
    "official_title": "A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts",
    "inclusion_criteria": "* Be healthy, immunocompetent males or females ≥ 18 years of age\n* Present with ≥ 2 and ≤ 30 external genital and/or perianal warts in ≥ 1 of the following anatomic areas:\n\n  * In both sexes: medial thigh (except inguinal fold); supra-pubic, perineal, and perianal areas\n  * In men: over the glans penis (excluding urethral meatus), penis shaft, scrotum, and foreskin\n  * In women: vulva (excluding labia minora and mucosal surfaces)\n* Have warts present for ≥ 4 weeks at the baseline visit\n* Have warts that are ≤ 8 mm in diameter each\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have a wart within the allowed treatment area > 8 mm in diameter or with an eroded or ulcerated surface, in the Investigator's opinion\n* Have an unclear diagnosis of condyloma\n* Have any wart types other than genital warts (e.g., common or plantar warts) that require treatment during the study period\n* Have active genital herpes eruption, or had active genital herpes lesions within 4 weeks before enrollment\n* Have a history of neoplasia or other HPV-associated malignancies within the last 5 years\n* Are systemically immunosuppressed\n* Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods\n* Are pregnant or breastfeeding",
    "miscellaneous_criteria": "Key"
}